These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 24048276)

  • 1. CYP2C9 polymorphism is not a major determinant of bosentan exposure in healthy volunteers.
    Markert C; Burhenne J; Weiss J; Mikus G; Haefeli WE
    Clin Pharmacol Ther; 2014 Mar; 95(3):250-1. PubMed ID: 24048276
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to "CYP2C9 polymorphism is not a major determinant of bosentan exposure in healthy volunteers".
    Markova SM; Schwartz JB; Kroetz DL
    Clin Pharmacol Ther; 2014 Mar; 95(3):252. PubMed ID: 24346422
    [No Abstract]   [Full Text] [Related]  

  • 3. CYP2C9, SLCO1B1, SLCO1B3, and ABCB11 polymorphisms in patients with bosentan-induced liver toxicity.
    Roustit M; Fonrose X; Montani D; Girerd B; Stanke-Labesque F; Gonnet N; Humbert M; Cracowski JL
    Clin Pharmacol Ther; 2014 Jun; 95(6):583-5. PubMed ID: 24842639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Managing the risk of drug-induced liver injury.
    Watkins PB
    Clin Pharmacol Ther; 2013 Dec; 94(6):629-31. PubMed ID: 24241638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of CYP2C9*2 with bosentan-induced liver injury.
    Markova SM; De Marco T; Bendjilali N; Kobashigawa EA; Mefford J; Sodhi J; Le H; Zhang C; Halladay J; Rettie AE; Khojasteh C; McGlothlin D; Wu AH; Hsueh WC; Witte JS; Schwartz JB; Kroetz DL
    Clin Pharmacol Ther; 2013 Dec; 94(6):678-86. PubMed ID: 23863877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-related hepatotoxicity.
    McIntyre K
    N Engl J Med; 2006 May; 354(20):2191-3; author reply 2191-3. PubMed ID: 16710914
    [No Abstract]   [Full Text] [Related]  

  • 7. Combined use of ursodeoxycholic acid and bosentan prevents liver toxicity caused by endothelin receptor antagonist bosentan monotherapy: two case reports.
    Ito T; Ozaki Y; Son Y; Nishizawa T; Amuro H; Tanaka A; Tamaki T; Nomura S
    J Med Case Rep; 2014 Jul; 8():250. PubMed ID: 25015229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Achilles heel of endothelin receptor therapy for pulmonary arterial hypertension.
    Corris PA; Langleben D
    Eur Respir J; 2010 Feb; 35(2):460-1; author reply 461. PubMed ID: 20123858
    [No Abstract]   [Full Text] [Related]  

  • 9. Genetic susceptibility to hepatoxicity due to bosentan treatment in pulmonary hypertension.
    Seyfarth HJ; Favreau N; Tennert C; Ruffert C; Halank M; Wirtz H; Mössner J; Rosendahl J; Kovacs P; Wittenburg H
    Ann Hepatol; 2014; 13(6):803-9. PubMed ID: 25332267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Blockade of endothelin receptor with bosentan--a new principle of treatment in pulmonary arterial hypertension].
    Nielsen-Kudsk JE
    Ugeskr Laeger; 2003 Jul; 165(29):2891-4. PubMed ID: 12908360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatotoxicity by bosentan in a patient with portopulmonary hypertension: a case-report and review of the literature.
    Eriksson C; Gustavsson A; Kronvall T; Tysk C
    J Gastrointestin Liver Dis; 2011 Mar; 20(1):77-80. PubMed ID: 21451802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe hepatotoxicity in a patient on bosentan upon addition of methotrexate: reversible with resumption of methotrexate without bosentan.
    Dwyer N; Jones G; Kilpatrick D
    J Clin Rheumatol; 2009 Mar; 15(2):88-9. PubMed ID: 19265355
    [No Abstract]   [Full Text] [Related]  

  • 13. [Bosentan: a considerable increase in the survival of patients with pulmonary hypertension associated with systemic rheumatic diseases].
    Volkov AV; Iudkina NN; Nikolaeva EV; Kurmukov IA; Glukhova SI; Nasonov EL
    Ter Arkh; 2014; 86(5):32-9. PubMed ID: 25026800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hidden hazards of Bosentan therapy in pulmonary hypertension.
    Sethi S; Sethi R; Wareham C
    Ann Card Anaesth; 2008; 11(2):138; author reply 138-9. PubMed ID: 18603762
    [No Abstract]   [Full Text] [Related]  

  • 15. Drug eruption due to bosentan in a patient with systemic sclerosis.
    Nagai Y; Yamanaka M; Nishimura S; Nakano A; Hasegawa A; Ishikawa O
    Mod Rheumatol; 2006; 16(3):188-90. PubMed ID: 16767560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hepatotoxicity in patients treated with endothelin receptor antagonists: systematic review and meta-analysis of randomized clinical trials].
    Macías Saint-Gerons D; de la Fuente Honrubia C; Montero Corominas D; Catalá-López F
    Med Clin (Barc); 2014 Apr; 142(8):333-42. PubMed ID: 23540381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative safety and tolerability of endothelin receptor antagonists in pulmonary arterial hypertension.
    Aversa M; Porter S; Granton J
    Drug Saf; 2015 May; 38(5):419-35. PubMed ID: 25792028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of pulmonary arterial hypertension: endothelin-receptor antagonists].
    Hoeper MM
    Dtsch Med Wochenschr; 2006 Dec; 131(49 Suppl 9):S308-10. PubMed ID: 17139593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the Metabolic Pathway of Bosentan and of the Cytotoxicity of Bosentan Metabolites Based on a Quantitative Modeling of Metabolism and Transport in Sandwich-Cultured Human Hepatocytes.
    Matsunaga N; Kaneko N; Staub AY; Nakanishi T; Nunoya K; Imawaka H; Tamai I
    Drug Metab Dispos; 2016 Jan; 44(1):16-27. PubMed ID: 26502773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver toxicity of sitaxentan in pulmonary arterial hypertension.
    Galiè N; Hoeper MM; Simon J; Gibbs R; Simonneau G;
    Eur Heart J; 2011 Feb; 32(4):386-7. PubMed ID: 21416695
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.